Articles tagged with Small Molecule Inhibitors
Researchers at Insilico Medicine have developed novel small molecular inhibitors and extremely selective PROTACs targeting the serine/threonine kinase PKMYT1. The discovery utilizes noncovalent interactions to achieve selectivity, masking hydrogen-bond donors that negatively affect permeability and solubility.
Researchers at VCU Massey Comprehensive Cancer Center developed a targeted therapy that effectively prevents prostate tumors from spreading to the bone. The small molecule inhibitor IVMT-Rx-4 blocks the function of MDA-9/Syntenin, preventing tumor growth and improving survival in models with bone metastasis.
Insilico Medicine will present four novel cancer inhibitors discovered via its Pharma.AI platform, targeting KRAS and Cbl-b pathways. ISM6166 and ISM3830 demonstrate robust anti-tumor activity against solid tumors with KRAS alterations and restored innate and adaptive immunity, respectively.
ISM4808, a PHD inhibitor for chronic kidney disease-related anemia, has achieved its first milestone with successful completion of the Phase I clinical trial. The treatment stimulates endogenous erythropoietin production and improves iron utilization, offering improved efficiency and safety compared to existing treatments.
Insilico Medicine has received investigational new drug (IND) clearance from the US FDA for ISM8969, an orally available NLRP3 inhibitor targeting inflammation and neurodegenerative disorders. The Phase I clinical trial plans to evaluate the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers.
The companies will jointly develop ISM8969, a brain penetrant NLRP3 inhibitor for treating neuroinflammation-related diseases. Preclinical data shows the molecule's efficacy and favorable safety profile.
Insilico Medicine and Taigen Biotechnology collaborate to develop and commercialize ISM4808, an AI-driven PHD inhibitor for treating anemia of Chronic Kidney Disease (CKD). The partnership grants TaiGen exclusive rights for further development, commercialization, and sub-licensing in the Greater China area.
Researchers at Insilico Medicine developed an AI-empowered dual-action PROTAC targeting PKMYT1, which induces degradation and inhibits kinase activity. The lead compound, D16-M1P2, exhibits high selectivity, potent anti-tumor activity, and favorable oral bioavailability.
Insilico Medicine has nominated ISM3830, a highly selective CBLB inhibitor, as a preclinical candidate for advanced tumor immunotherapy. ISM3830 showed robust anti-tumor activity in multiple murine models and induction of long-term tumor immunity.
The collaboration combines Insilico's Pharma.AI platforms with Lilly's expertise to discover and advance new therapies. Insilico will utilize its platform to generate candidate compounds, accelerating the development of transformative treatments for urgent patient needs.
Pharma.AI is a comprehensive generative AI-powered drug discovery platform featuring PandaOmics, Generative Biologics, Chemistry42, Science42: DORA, and PreciousGPT. These platforms enhance target and biomarker discovery, biologics engineering, small molecule design, scientific research, and disease modelling.
A potent new dual lipid kinase inhibitor, RMC-113, selectively inhibits PIKfyve and PIP4K2C, providing a potential strategy to combat emerging viruses. The study reveals that PIP4K2C plays a crucial role in SARS-CoV-2 entry, replication, and assembly/egress, making it an understudied kinase with significant antiviral potential.
Insilico Medicine has completed the first-in-patient dosing of ISM3412, a novel MAT2A inhibitor with potential as a best-in-class treatment for locally advanced and metastatic solid tumors. The Phase 1 study aims to evaluate safety, tolerability, and preliminary anti-tumor efficacy of ISM3412.
The Phase IIa trial of Rentosertib showed encouraging clinical data, with patients receiving the treatment experiencing significant improvements in lung function compared to placebo. The study also validated the biological mechanism of TNIK inhibition using exploratory biomarkers analyses.
This study reveals periostin as a superior serum biomarker for diagnosing idiopathic pulmonary fibrosis, with high sensitivity and specificity compared to traditional markers. Periostin levels also correlate with disease severity and predict acute exacerbations in IPF patients.
Scientists have developed the most broadly effective antivenom to date, neutralizing the neurotoxins of 19 deadly snakes including black mambas and king cobras. The antivenom combines protective antibodies and a small molecule inhibitor, offering a potential universal solution for snakebite victims.
Researchers at Texas Tech University Health Sciences Center have received a $1.94 million grant to study inhibitors that target peripheral neuropathic pain. The project aims to develop novel non-opioid and non-addicting therapies capable of effectively managing chronic pain.
Researchers have discovered RNA pseudouridine as a novel diagnostic target for colorectal cancer. The study found correlations between pseudouridine modifications and clinical markers, enabling potential non-invasive diagnosis. The findings provide a molecular framework for RNA epigenetics-based stratification and targeted interventions.
Researchers found that inhibiting WNT signaling after the hemogenic endothelium stage enhances blood progenitor formation from pluripotent stem cells. This strategy corrects intrinsic deficiencies and brings in vitro-derived HSPCs closer to their in vivo counterparts.
Researchers at Sanford Burnham Prebys have discovered a way to target the energy supply chain of cancer cells. By understanding how enzymes like ubiquitous mitochondrial creatine kinase (uMtCK) function, scientists can design new treatments that slow or stop tumor growth.
A groundbreaking study using AI-driven robotics laboratory identifies Rentosertib, a potent TNIK inhibitor, as a highly effective senomorphic agent capable of reducing aging-related markers. The study reveals TNIK inhibition alleviates key signaling pathways implicated in senescence and fibrosis.
The Menarini Group and Insilico Medicine have entered into an exclusive licensing agreement for a preclinical small molecule targeting solid tumor cancers. The asset has demonstrated broad anti-tumor activity in selected cancers, offering new treatment options for cancer patients with high unmet needs.
Positive Phase 1 trial results suggest ISM5411's gut-restrictive property and favorable pharmacokinetic profile, validating its potential for treating inflammatory bowel disease. Insilico Medicine expects to initiate a Phase 2 proof-of-concept study in active ulcerative colitis patients.
Scientists at Insilico Medicine developed a novel gut-restricted PHD inhibitor using generative chemistry engine Chemistry42, promising to repair intestinal mucosal barriers and regulate immune responses in IBD. The compound, ISM5411, demonstrated significant anti-colitis activity without systemic side effects.
A new oral medication, muvalaplin, has shown promising results in lowering lipoprotein(a) levels, a marker of cardiovascular risk. The study's findings suggest that muvalaplin may be a valuable treatment option for individuals with high lipoprotein(a) levels.
A team of researchers at the University of Toronto has developed a rapid screening system to identify compounds that can stop the growth of amyloid proteins. The study found 40 compounds that demonstrate the ability to inhibit amyloid formation, providing a promising lead for future disease treatments.
Researchers at Weill Cornell Medicine have developed a virtual screening approach to identify small molecule drug candidates targeting cancer checkpoints. The method successfully identified two compounds with potential therapeutic activity against TIM-3 and VISTA inhibitory checkpoints.
Researchers identified a crucial protein, TIMP3, overproduced in AMD and found that blocking its activity can reduce drusen formation, suggesting a promising treatment strategy. The study offers new avenues for preventing AMD and improving the lives of millions affected by this disease.
Researchers at Purdue University have received an additional $95,000 from the Trask Innovation Fund to further de-risk their technology for patent-pending drought-resistant soybean plants. Herman Sintim's team aims to develop novel compounds that potentially inhibit TAK1, a protein kinase shown to play key roles in arthritis.
A new study from Michigan Medicine suggests that inhibiting the SWI/SNF epigenetic complex can therapeutically target oncogenic transcription factors. The research, led by Arul Chinnaiyan, builds on previous work to find genetic vulnerabilities in transcription factor-driven cancers.
Researchers have identified a potent and unique way to kill drug-resistant bacteria using a repurposed compound called LEI-800. The compound targets the bacterial enzyme DNA gyrase, which is essential for bacterial growth and has not been targeted by existing antibiotics.
Researchers developed a novel approach to block cancer cell growth by targeting specific proteins, reducing side effects and increasing treatment efficacy. The method uses antibody-peptide inhibitor conjugates, which deliver inhibitors specifically to cancer cells,
Researchers at Hollings Cancer Center have identified a promising therapeutic strategy to combat pancreatic cancer. By simultaneously blocking HSP70 and autophagy, the growth of pancreatic tumors can be slowed, offering new hope for treatment.
A team of researchers led by Dr. Ahmed discovered that two FDA-approved antibiotics can induce heart regeneration in mammals, showing promise for treating heart failure. The study found that the antibiotics improved cardiac output and reduced fibrotic scar tissue, suggesting a potential new therapy.
Insilico Medicine's lead compound demonstrates strong enzymatic activity, selectivity, and favorable ADME properties, as well as antitumor activity in various animal models. The company's generative AI-powered platform generated over 3,600 candidate molecules before identifying the promising lead compound.
Researchers at University of Kansas discover a new compound that inhibits SARS-CoV-2 replication in cell models by targeting the 'Mac-1' protein. This finding offers hope for developing new treatments and preventing future pandemics.
Researchers at the University of Eastern Finland have identified coregulator proteins as an alternative target to prevent drug resistance in prostate cancer. By inhibiting these proteins, the growth of drug-resistant cancer cells can be inhibited, and the activity of the glucocorticoid receptor can be limited.
Researchers found elevated PROX1 levels in advanced colon adenocarcinoma, correlating with poor prognosis. PROX1 modulates CRC cell behavior, influencing invasiveness and survival outcomes. The combined PROX1/α-SMA gene set emerges as a potential CRC prognostic marker.
Scientists found that short-chain fatty acids produced by gut bacteria suppress allergic reactions by modulating mast cell activation and epigenetic modifications. This study provides new insights into the relationship between diet and immune system regulation, with potential applications in allergy treatment.
Researchers discovered that microRNA-29 can restore normal skin structure rather than producing a scar, promoting faster and more efficient wound healing. The release of microRNA-29 targets, particularly LAMC2, is crucial in this process, suggesting a potential new approach for treating large-area or deep wounds.
Insilico Medicine has discovered a novel PHD inhibitor for treating anemia using its AI-powered generative chemistry platform Chemistry42. The compound demonstrated favorable ADMET and PK profiles in animal models, showing promise for further investigations.
Researchers at Insilico Medicine have identified MYT1 as a promising therapeutic target for breast and gynecological cancers. A series of novel, potent, and highly selective inhibitors specifically targeting MYT1 were discovered using AI-driven generative biology and chemistry engine.
Researchers unveiled a previously unknown effect of PG545 in ovarian cancer cells, inducing DNA damage and promoting autophagic degradation of RAD51. This breakthrough could aid in selecting the most appropriate treatments for ovarian cancer patients with PARPi resistance.
GFH009 inhibits tumor growth and induces apoptosis in various HHM-derived cell lines. The compound's mechanism of action involves rapid 'on-off' inhibition of CDK9, which exerts a proapoptotic effect on cancer cells.
Researchers at TTUHSC are studying a new approach to inhibit STAT3, a protein associated with 70% of human tumors. Disrupting STAT3 synthesis on ribosomes could lead to new cancer treatments.
Researchers at University of Cincinnati Cancer Center present Phase 2 clinical trial results for a new BTK inhibitor treatment that offers potential for improved efficacy and safety in chronic lymphocytic leukemia. The study also explores the use of IRAK4 inhibitors to target acute myeloid leukemia cells, with promising results.
Researchers have developed a new method, SECRE, to identify genetic regulators of cytokine secretion in autoimmune diseases. The technique has been validated on cells known to play a crucial role in inflammatory bowel disease (IBD) and shows promising results for treating conditions with few therapeutic options.
A team of researchers at Massachusetts General Hospital has identified a new small molecule inhibitor, PB118, that significantly reduces Alzheimer's disease neuropathology. The inhibitor targets histone deacetylase 6 (HDAC6), which is overexpressed in the brain of AD patients.
Researchers developed novel small molecule inhibitors of CPSF3, a key regulator of transcription termination in ovarian cancer cells. These inhibitors exhibited potent antiproliferative effects and suppressed tumor growth in vivo.
Researchers at MUSC Hollings Cancer Center have identified new targets for treating breast cancer that has become resistant to hormone therapy and CDK4/6 inhibitors. By understanding the molecular mechanisms of resistance, the team has found potential solutions using epidermal growth factor receptors and PARP inhibitors.
Researchers have found that targeting protein eIF4A with the small molecule drug Zotatifin can suppress tumor cell proliferation and remodel the immune microenvironment in triple-negative breast cancer. The promising findings support pursuing clinical trials to assess the potential patient benefits of this approach.
Researchers at Baylor College of Medicine identified a small molecule named 5D4 that can suppress breast and ovarian cancer growth. 5D4 works by binding to TopBP1 protein in cancer cells, disrupting interactions with multiple pathways that promote cancer growth. Combining 5D4 with PARP inhibitors enhances anti-cancer activity.
Researchers found that inhibiting an enzyme associated with aging accelerates nerve regeneration and restores strength in damaged nerves. By targeting the gerozyme 15-PGDH, they promote neuromuscular synapses and faster recovery from peripheral nerve injuries.
A new compound developed at the University of Illinois Chicago potentially offers an alternative to injections for wet age-related macular degeneration, a leading cause of blindness. The drug targets End Binding-3 and has been shown to reverse damage and promote regenerative processes in animal models.
Preclinical data shows GP-2250's antineoplastic activity in pancreatic tumor cell lines, reducing ATP levels and inhibiting NF-kB. The compound targets aerobic glycolysis, a hallmark of cancer metabolism, providing a potential treatment for various cancers.
Muvalaplin, an oral small molecule inhibitor, significantly lowered lipoprotein(a) (Lp[a]) levels in a first-in-human phase 1 study. The treatment showed promise in reducing Lp[a] levels by up to 65% without tolerability concerns.
The Texas Heart Institute has been awarded $1.14 million by the NIH to develop a novel, first-in-class drug for treating atherosclerotic cardiovascular disease. The goal of this research is to target lingering inflammation in patients with cardiovascular disease.
A new antibiotic strategy has been found to defeat gram-negative bacteria like Salmonella and E. coli by interfering with the outer lipid layer of the bacteria. The compound, LPC-233, is a small molecule that works fast and is durable in animal tests, with potentially vital applications against stubborn urinary tract infections.
Researchers developed innovative techniques to treat challenging cancers and manage therapy side effects. Inhibitors targeting PRMT5, a histone-modifying enzyme, alleviated cisplatin-induced hearing loss, while nano-pills delivered combination drugs to liver cancer cells.
Researchers propose targeting non-canonical HH/GLI signaling to improve response rate and durability of therapeutic effects exerted by SMO inhibition in melanoma. The findings suggest that combined targeting of hedgehog signaling and BRD4 could provide a novel therapeutic option against melanoma.